Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PRC2 Restricts Malignant Peripheral Nerve Sheath Tumorigenesis in a Genetically Engineered Mouse Model of MPNST.

bioRxiv : the preprint server for biology·2025
Same author

DNA Methylation Profiling Classifies and Reveals Origin of Gynecologic Central Nervous System-Like Tumors.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2025
Same author

Deep-Learning Tool ScVital Enables Species-Agnostic Integration of Cancer Cell States.

Cancer research·2025
Same author

Spectrum and Clinical Impact of Secondary Genetic Alterations in Translocation-Associated Sarcomas.

JCO precision oncology·2025
Same author

PRRX1 -rearranged Fibroblastic Tumors : A Clinicopathologic and Molecular Study of 18 Cases Including a Novel PRRX1::EP300 Fusion.

The American journal of surgical pathology·2025
Same author

NFATC2::NUTM2A/B Fusions Characterize a Novel Indolent Myoepithelial-Like Neoplasm of the Lungs and Salivary Glands.

Genes, chromosomes & cancer·2025
Same journal

Pathobiology and Interactions of the MiTF Signaling Pathways.

Advances in anatomic pathology·2026
Same journal

Diagnosis and Reporting of Intraductal Carcinoma of the Prostate: A Guide for Practising Pathologists With Excerpts From the Genitourinary Pathology Society and the International Society of Urological Pathology Joint Expert Consultation.

Advances in anatomic pathology·2026
Same journal

An Update on Soft Tissue Tumors of the Paratesticular Region.

Advances in anatomic pathology·2026
Same journal

Recognizing Familial Thyroid Neoplasia: The Pathologist's Role in Diagnosis and Management.

Advances in anatomic pathology·2026
Same journal

Hereditary and Familial Tumor Syndromes: When to Think of Them? The Emerging Role of Pathologists as Sentinels of Genetic Cancer Predisposition.

Advances in anatomic pathology·2026
Same journal

From Familial Clustering to a Dedicated Classification: The Historical Recognition of Hereditary Tumor Syndromes in the WHO Classification of Tumors.

Advances in anatomic pathology·2026
See all related articles

Related Experiment Video

Updated: Jan 15, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.9K

Alveolar Soft Part Sarcoma: An Updated Review.

Pedram Argani1,2, Cristina R Antonescu3

  • 1Departments of Pathology.

Advances in Anatomic Pathology
|October 16, 2025
PubMed
Summary
This summary is machine-generated.

Alveolar soft part sarcoma (ASPS) is a rare cancer. Research has identified its genetic cause, the ASPSCR1::TFE3 gene fusion, clarifying its origin as a unique tumor type.

Keywords:
TFE3alveolar soft part sarcomasarcoma

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.2K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.6K

Related Experiment Videos

Last Updated: Jan 15, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.9K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.2K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.6K

Area of Science:

  • Oncology
  • Genetics
  • Pathology

Background:

  • Alveolar soft part sarcoma (ASPS) was first described in 1952.
  • The cell of origin for ASPS remained controversial for decades.
  • Recent advances have elucidated the genetic underpinnings of ASPS.

Purpose of the Study:

  • To review the clinical and pathologic features of alveolar soft part sarcoma.
  • To discuss the current understanding of ASPS based on genetic discoveries.
  • To highlight the significance of gene fusion-driven neoplasms.

Main Methods:

  • Review of historical and recent scientific literature.
  • Analysis of clinical case data.
  • Genetic analysis of tumor samples.

Main Results:

  • The der(17)t(X;17)(p11;q25) translocation and ASPSCR1::TFE3 gene fusion were identified in 2001.
  • ASPS is now understood as a gene fusion-driven sarcoma.
  • These tumors lack a normal cellular counterpart.

Conclusions:

  • The identification of the ASPSCR1::TFE3 fusion has resolved the longstanding debate on ASPS origin.
  • Alveolar soft part sarcomas are a distinct group of neoplasms characterized by specific genetic alterations.
  • Understanding the molecular basis of ASPS is crucial for its diagnosis and potential therapeutic strategies.